RG-7410

RG-7410 is a trace amine-associated receptor 1 (TAAR1) agonist which was under development for the treatment of schizophrenia but was never marketed.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

RG-7410 is a trace amine-associated receptor 1 (TAAR1) agonist which was under development for the treatment of schizophrenia but was never marketed. Its route of administration was unspecified. The drug reached phase 1 clinical trials prior to the discontinuation of its development.

It was under development by Hoffmann-La Roche. RG-7410 was first disclosed by January 2014 and a phase 1 trial was reported to have been completed by October 2014.

See also

List of investigational antipsychotics Ralmitaront (RG-7906; RO-6889450) RG-7351 Ulotaront (SEP-363856; SEP-856)

Text derived from https://en.wikipedia.org/w/index.php?oldid=1357690383 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

4 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.